Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status: A retrospective analysis

High Blood Pressure and Cardiovascular Prevention

Volumn 19, Issue 4, 2012, Pages 213-222

  Malacco, Ettore ^a   Omboni, Stefano ^b   Mallion, Jean Michel ^c   Volpe, Massimo ^d,e  

^a UNIVERSITY OF MILAN   (Italy)

^b ITALIAN INSTITUTE OF TELEMEDICINE   (Italy)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e IRCCS NEUROMED   (Italy)

Author keywords

Elderly; Hypertension, treatment; Olmesartan medoxomil, therapeutic use; Ramipril, therapeutic use; Renal function

Indexed keywords

HYDROCHLOROTHIAZIDE; OLMESARTAN; PLACEBO; RAMIPRIL; ZOFENOPRIL;

AGED; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; ESSENTIAL HYPERTENSION; FOLLOW UP; FUNCTIONAL STATUS; GERIATRIC PATIENT; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHI-SQUARE DISTRIBUTION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; IMIDAZOLES; KIDNEY; MALE; MULTICENTER STUDIES AS TOPIC; RAMIPRIL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84873461238     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.1007/bf03297633     Document Type: Article

References (67)

1. Olyaei AJ, Bennett WM. Drug dosing in the elderly patients with chronic kidney disease. Clin Geriatr Med 2009 Aug; 25 (3) 459-527
2. Olyaei AJ Bennett WM Drug dosing in the elderly patients with chronic kidney disease Clin Geriatr Med 2009 Aug 25 3 459-527
3. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management a European Society of Hypertension Task Force document. J Hypertens 2009 Nov; 27 (11) 2121-58
4. Mancia G Laurent S Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management a European Society of Hypertension Task Force document J Hypertens 2009 Nov 27 11 2121-58
5. Brenner BM, Cooper ME, de Zeeuw D, et al., RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345 861-9
6. Brenner BM Cooper ME de Zeeuw D et al. RENAAL Study Investigators Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 2001 345 861-9
7. Lewis EJ, Hunsicker LG, Clarke WR, et al., Collaborative Study Group. Renoprotective effect of the angiotensiN-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001 Sep 20; 345 (12) 851-60
8. Lewis EJ Hunsicker LG Clarke WR et al. Collaborative Study Group Renoprotective effect of the angiotensiN-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 2001 Sep 20 345 12 851-60
9. Viberti G, Mogensen CE, Groop LC, et al. Effect of captopril on progression to clinical proteinuria in patients with insuliN-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994 Jan 26; 271 (4) 275-9
10. Viberti G Mogensen CE Groop LC et al. Effect of captopril on progression to clinical proteinuria in patients with insuliN-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group JAMA 1994 Jan 26 271 4 275-9
11. Parving HH, Lehnert H, Bröchner-Mortensen J, et al., Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001 Sep 20; 345 (12) 870-8
12. Parving HH Lehnert H Bröchner-Mortensen J et al. , Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 2001 Sep 20 345 12 870-8
13. Viberti G, Wheeldon NM, for the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus a blood pressure-independent effect. Circulation 2002 Aug 6; 106 (6) 672-8
14. Viberti G Wheeldon NM for the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus a blood pressure-independent effect Circulation 2002 Aug 6 106 6 672-8
15. Destro M, Preti P, D'Ospina A, et al. Olmesartan medoxomil recent clinical and experimental acquisitions. Expert Opin Drug Metab Toxicol 2009; 5 1149-57
16. Destro M Preti P D'Ospina A et al. Olmesartan medoxomil recent clinical and experimental acquisitions Expert Opin Drug Metab Toxicol 2009 5 1149-57
17. Scott LJ, McCormack PL. Olmesartan medoxomil a review of its use in the management of hypertension. Drugs 2008; 68 (9) 1239-72
18. Scott LJ McCormack PL Olmesartan medoxomil a review of its use in the management of hypertension Drugs 2008 68 9 1239-72
19. Heagerty AM, Mallion JM. Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension efficacy and safety data from clinical trials. Drugs Aging 2009; 26 61-76
20. Heagerty AM Mallion JM Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension efficacy and safety data from clinical trials Drugs Aging 2009 26 61-76
21. Mallion JM, Heagerty A, Laeis P. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. J Hypertens 2007 Oct; 25 (10) 2168-77
22. Mallion JM Heagerty A Laeis P Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension J Hypertens 2007 Oct 25 10 2168-77
23. Malacco E, Omboni S, Volpe M, et al. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension the ESPORT study. J Hypertens 2010 Nov; 28 (11) 2342-50
24. Malacco E Omboni S Volpe M et al. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension the ESPORT study J Hypertens 2010 Nov 28 11 2342-50
25. Mallion JM, Omboni S, Barton J, et al. Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension. Blood Press 2011 Apr; 20 Suppl. 1 3-11
26. Mallion JM Omboni S Barton J et al. Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension Blood Press 2011 Apr 20 3-11
27. O'Brien E, Atkins N, Stergiou G, et al., Working Group on Blood Pressure Monitoring of the European Society of Hypertension. European Society of Hypertension International Protocol revision 2010 for the validation of blood pressure measuring devices in adults. Blood Press Monit 2010 Feb; 15 (1) 23-38
28. O'Brien E Atkins N Stergiou G et al. Working Group on Blood Pressure Monitoring of the European Society of Hypertension European Society of Hypertension International Protocol revision 2010 for the validation of blood pressure measuring devices in adults Blood Press Monit 2010 Feb 15 1 23-38
29. O'Brien E, Asmar R, Beilin L, et al., European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003 May; 21 (5) 821-48
30. O'Brien E Asmar R Beilin L et al. European Society of Hypertension Working Group on Blood Pressure Monitoring European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement J Hypertens 2003 May 21 5 821-48
31. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 31-41
32. Cockcroft DW Gault MH Prediction of creatinine clearance from serum creatinine Nephron 1976 16 31-41
33. Péquignot R, Belmin J, Chauvelier S, et al. Renal function in older hospital patients is more accurately estimated using the Cockcroft-Gault formula than the modification diet in renal disease formula. J Am Geriatr Soc 2009 Sep; 57 (9) 1638-43
34. Péquignot R Belmin J Chauvelier S et al. Renal function in older hospital patients is more accurately estimated using the Cockcroft-Gault formula than the modification diet in renal disease formula J Am Geriatr Soc 2009 Sep 57 9 1638-43
35. Christensson A, Elmstahl S.. Estimation of the age-dependent decline of glomerular filtration rate from formulas based on creatinine and cystatin C in the general elderly population. Nephron Clin Pract 2011; 117 (1) c40-50
36. Christensson A Elmstahl S. Estimation of the age-dependent decline of glomerular filtration rate from formulas based on creatinine and cystatin C in the general elderly population Nephron Clin Pract 2011 117 1 c40-50
37. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17 863-71
38. Du Bois D Du Bois EF A formula to estimate the approximate surface area if height and weight be known Arch Intern Med 1916 17 863-71
39. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification and stratification. Am J Kidney Dis 2002; 39 Suppl. 1 S1-S266
40. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification and stratification Am J Kidney Dis 2002 39;S1-S266
41. National Institute for Health and Clinical Excellence. Chronic kidney disease (CG73). London National Institute for Health and Clinical Excellence, 2008
42. National Institute for Health and Clinical Excellence Chronic kidney disease (CG73) LondonNational Institute for Health and Clinical Excellence 2008
43. Barnett A. Preventing renal complications in type 2 diabetes results of the diabetics exposed to telmisartan and enalapril trial. J Am Soc Nephrol 2006 Apr; 17 Suppl. 2 132-5
44. Barnett A Preventing renal complications in type 2 diabetes results of the diabetics exposed to telmisartan and enalapril trial J Am Soc Nephrol 2006 Apr 17 132-5
45. Turgut F, Balogun RA, Abdel-Rahman EM. ReniN-angiotensiN-aldosterone system blockade effects on the kidney in the elderly benefits and limitations. Clin J Am Soc Nephrol 2010 Jul; 5 (7) 1330-9
46. Turgut F Balogun RA Abdel-Rahman EM ReniN-angiotensiN-aldosterone system blockade effects on the kidney in the elderly benefits and limitations Clin J Am Soc Nephrol 2010 Jul 5 7 1330-9
47. US Renal Data System (USRDS). 2011 Annual data report atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda (MD) National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2011
48. US Renal Data System (USRDS) 2011 Annual data report atlas of chronic kidney disease and end-stage renal disease in the United StatesBethesda (MD) National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2011
49. Bakris GL, Ritz E, World Kidney Day Steering Committee. The message for World Kidney Day 2009 hypertension and kidney disease – a marriage that should be prevented. J Hypertens 2009 Mar; 27 (3) 666-9
50. Bakris GL Ritz E World Kidney Day Steering Committee The message for World Kidney Day 2009 hypertension and kidney disease – a marriage that should be prevented J Hypertens 2009 Mar; 27(3) 666-9.
51. Ruilope LM. Current challenges in the clinical management of hypertension. Nat Rev Cardiol 2011; 9 (5) 267-75
52. Ruilope LM Current challenges in the clinical management of hypertension Nat Rev Cardiol 2011 9 5 267-75
53. Ohishi M, Takeya Y, Tatara Y, et al. Strong suppression of the reniN-angiotensin system has a renal-protective effect in hypertensive patients high-dose ARB with ACE inhibitor (Hawaii) study. Hypertens Res 2010 Nov; 33 (11) 1150-4
54. Ohishi M Takeya Y Tatara Y et al. Strong suppression of the reniN-angiotensin system has a renal-protective effect in hypertensive patients high-dose ARB with ACE inhibitor (Hawaii) study Hypertens Res 2010 Nov 33 11 1150-4
55. Haller H, Ito S, Izzo Jr JL, et al., ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011 Mar 10; 364 907-17
56. Imai E, Chan JC, Ito S, et al., for the ORIENT study investigators. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy a multicentre, randomised, placebo-controlled study. Diabetologia 2011 Dec; 54 (12) 2978-86
57. Imai E Chan JC Ito S et al. for the ORIENT study investigators Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy a multicentre, randomised, placebo-controlled study Diabetologia 2011 Dec; 54 (12)2978-86
58. GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, noN-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997 Jun 28; 349 1857-63
59. GISEN Group Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, noN-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Lancet. 1997 Jun 28; 349;1857-63.
60. Ruggenenti P, Perna A, Benini R, et al. In chronic nephropathies prolonged ACE inhibition can induce remission dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc Nephrol 1999 May; 10 (5) 997-1006
61. Ruggenenti P Perna A Benini R et al. In chronic nephropathies prolonged ACE inhibition can induce remission dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia J Am Soc Nephrol 1999 May 10 5 997-1006
62. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensiN-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 Jan 20; 342 (3) 145-53
63. Yusuf S Sleight P Pogue J et al. Effects of an angiotensiN-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 2000 Jan 20 342 3 145-53
64. Rodby RA, Rohde RD, Clarke WR, et al., for the Collaborative Study Group. The Irbesartan Type II Diabetic Nephropathy Trial study design and baseline patient characteristics. Nephrol Dial Transplant 2000 Apr; 15 (4) 487-97
65. Rodby RA Rohde RD Clarke WR et al. for the Collaborative Study Group The Irbesartan Type II Diabetic Nephropathy Trial study design and baseline patient characteristics Nephrol Dial Transplant 2000 Apr 15 4 487-97
66. Mann JF, Schmieder RE, McQueen M, et al., ONTARGET Investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study) a multicentre, randomised, double-blind, controlled trial. Lancet 2008 Aug 16; 372 (9638) 547-53
67. Mann JF Schmieder RE McQueen M et al. ONTARGET Investigators Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study) a multicentre, randomised, double-blind, controlled trial Lancet 2008 Aug 16 372 9638 547-53